Abstract 5-Fluorouracil (5-FU) is a widely prescribed chemotherapy for colorectal, breast, gastric, and head and neck cancers. The drug inhibits thymidylate synthase, blocking DNA synthesis and causing cytotoxic stress that halts tumor growth. However, patients carrying deleterious variants in DPYD, the gene encoding the rate-limiting enzyme in 5-FU metabolism (dihydropyrimidine dehydrogenase, DPD), can experience fatal toxicity due to impaired drug clearance and accumulation of 5-FU metabolites. Current pharmacogenetic screening guidelines in the U.S. recommend testing for few of the 2,000 nonsynonymous variants that have been reported for DPYD, leaving patients with rare, uncharacterized mutations at risk. To interpret expanded testing, however, a means to classify DPYD variants of unknown significance is needed. To address this, we developed MPACT-DPD, a random-forest-based classifier that accurately predicts the functional impact of DPYD missense variants. Our model was trained on in-vitro activity of 156 variants and leveraged a feature set of biochemical, evolutionary, and AlphaFold3-derived structural features. We optimized hyperparameters using ten-fold stratified cross-validation and evaluated model performance with Matthews correlation coefficient (MCC) to account for moderate class imbalance (7:3 neutral to deleterious). It achieved exceptional performance, with a Matthews correlation coeffient (MCC) of 0.906 and an accuracy of 95.1% on an independent validation set (n=43). Furthermore, a SHAP (SHapley Additive exPlanations)-based interpretability analysis revealed cofactor proximity and residue conservation as the key drivers of predictions. MPACT-DPD showed superior performance at variant classification against other tools, including a DPYD gene-specific variant classifier, and has the potential to expand pre-treatment genetic screening to improve the safety of personalized 5-FU-based chemotherapy. Citation Format: Lulu Jiang, Ryan Jonathan Swartz, Lauryn Allyn Hahn, Brianna Bembenek, Hannah Marie Krause, Kelly Bouchonville, Steven M. Offer. MPACT-DPD: An interpretable machine learning classifier for predicting the functional impact of DPYD missense variants abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2712.
Jiang et al. (Fri,) studied this question.